(Q28294793)
Statements
A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma (English)
0 references
February 2006
0 references
36
0 references
2
0 references
100-3
0 references